← FDA DRUG APPROVALS

FDA ANDA · ANDA080225

POTASSIUM CHLORIDE

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA080225
TYPE
ANDA
ORIGINAL APPROVAL
1971-06-30
LATEST ACTION
1994-12-06
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

POTASSIUM CHLORIDEDiscontinued
POTASSIUM CHLORIDE 3MEQ/ML · INJECTABLE · INJECTION
POTASSIUM CHLORIDE · ReferenceDiscontinued
POTASSIUM CHLORIDE 2MEQ/ML · INJECTABLE · INJECTION

Approval history

1994-12-06Manufacturing (CMC) · Supplement 47AP
1994-12-06Manufacturing (CMC) · Supplement 53AP
1993-01-13Labeling · Supplement 52AP
1992-11-25Labeling · Supplement 51AP
1991-04-26Labeling · Supplement 50AP
1990-12-18Labeling · Supplement 49AP
1990-06-01Labeling · Supplement 48AP
1987-10-28Manufacturing (CMC) · Supplement 44AP
1987-10-28Manufacturing (CMC) · Supplement 45AP
1984-11-27Manufacturing (CMC) · Supplement 41AP
1984-05-01Manufacturing (CMC) · Supplement 39AP
1984-02-13Manufacturing (CMC) · Supplement 38AP
1982-11-01Manufacturing (CMC) · Supplement 37AP
1982-06-23Manufacturing (CMC) · Supplement 34AP
1971-06-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →